This retrospective study aimed to estimate the economic burden associated with WPL in patients with psoriasis (Pso) in a US based population. Continuously enrolled adult patients with ≥2 Pso diagnoses were selected from the MarketScan Claims database (2004-2008). Pso patients were matched (based on age and gender) to continuously enrolled adult Pso-free patients (i.e., without diagnosis for Pso or psoriatic arthritis). WPL was estimated using workplace absenteeism and short term disability (STD) expenditures available in the MarketScan Health and Productivity Management database. Only patients for whom the employer recorded absenteeism and STD were included in the analysis. WPL, often referred to as total indirect cost, was defined as the sum of absenteeism costs (i.e., hours out of work for medical reasons [sick leave]* hourly wage) and STD costs (number of days on disability * daily wage). Wages were imputed based on the regions of residence using data from the U.S. Bureau of Labor Statistics. Annual incremental costs associated with WPL in Pso patients were stratified by Pso severity (mild or moderate-to-severe) and estimated using generalized linear models. Moderate-to-severe Pso patients were defined as patients who used systemic therapies during the 6-month baseline period; mild Pso patients did not use any systemic therapies during the baseline period. A total of 1137 matched pairs were included. Among Pso patients, 305 (26.8%) had moderate-to-severe Pso. After adjusting for confounding factors (age and gender), no significant cost differences associated with WPL were found when comparing mild Pso to Pso-free patients ($1827 for mild Pso vs. $1770 for Pso-free; difference= $52, p=0.825). When compared to Pso-free patients, however, moderate-to-severe Pso patients were associated with significant incremental WPL of $1026 per patient-year ($2781 for moderate-to-severe Pso vs. $1770 for Pso-free; p=0.014). Pso imparts a substantial WPL in patients with moderate-to-severe Pso.